[Whitepaper] A New Future for R&D? Measuring the return from pharmaceutical innovation 2017
Deloitte’s eight annual pharmaceutical innovation study looks at R&D in biopharma and estimates the ROI that 12 large-cap companies may expect to achieve. The report includes an extension cohort of four mid-tier companies.
Key findings for top 12 biopharma
- R&D returns have declined to 3.2 percent, from 10.1 percent in 2010
- It costs these companies almost $2bn to bring a drug to market
- Projected peak sales per asset more than halved between 2010 and 2016 but have increased by 18 percent in 2017
Emerging technology offers promise
Biopharma companies are starting to experiment with emerging technologies. For example:
- Artificial intelligence: can help analyze large data sets from sources such as clinical trials, health records, genetic profiles and pre-clinical studies; it can recognize patterns and trends and develop hypotheses at a much faster rate.
- Real-world evidence: can help revolutionize the way companies evaluate new therapies for safety and effectiveness. RWE can also help reduce the time it takes to recruit patients, identify subpopulations and conduct research.
- Robotic and cognitive automation: can automate work and streamline resources across the clinical trial value chain.
We believe that applying these emerging technologies can transform R&D.